WANY
TENX icon

Wealthspire Advisors (New York)’s Tenax Therapeutics TENX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$8 – 2708
2025
Q3 		$8 Buy
+1
New +$6 ﹤0.01% 3049

Other funds holding TENX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Wealthspire Advisors (New York)'s TENX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Tenax Therapeutics (TENX) in Q4 2025, closing a stake of 1 share — an estimated $8 sold.

Wealthspire Advisors (New York) first reported a position in TENX in Q3 2025 and held it in 1 quarter. The position peaked at $8 in Q3 2025. 48 funds tracked by Wall St. Rank hold TENX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Tenax Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 1 Tenax Therapeutics share in Q4 2025, an estimated $8.
  • Wealthspire Advisors (New York) first reported a position in Tenax Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Tenax Therapeutics position peaked at $8 in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.